miércoles, 5 de diciembre de 2018

The French National Registry of patients with Facioscapulohumeral muscular dystrophy | Orphanet Journal of Rare Diseases | Full Text

The French National Registry of patients with Facioscapulohumeral muscular dystrophy | Orphanet Journal of Rare Diseases | Full Text

Orphanet Journal of Rare Diseases

The French National Registry of patients with Facioscapulohumeral muscular dystrophy

  • ,
  • ,
  • ,
  • ,
  • ,
  • ,
  • ,
  • ,
  •  and
  • Email authorView ORCID ID profile
Contributed equally
Orphanet Journal of Rare Diseases201813:218
  • Received: 25 July 2018
  • Accepted: 22 November 2018
  • Published: 


Abstract

Background

Facioscapulohumeral muscular dystrophy is a rare inherited neuromuscular disease with an estimated prevalence of 1/20,000 and France therefore harbors about 3000 FSHD patients. With research progress and the development of targeted therapies, patients’ identification through registries can facilitate and improve recruitment in clinical trials and studies.

Results

The French National Registry of FSHD patients was designed as a mixed model registry involving both patients and physicians, through self-report and clinical evaluation questionnaires respectively, to collect molecular and clinical data. Because of the limited number of patients, data quality is a major goal of the registry and various automatic data control features have been implemented in the bioinformatics system. In parallel, data are manually validated by molecular and clinical curators. Since its creation in 2013, data from 638 FSHD patients have been collected, representing about 21% of the French FSHD population. The mixed model strategy allowed to collect 59.1% of data from both patients and clinicians; 26 and 14.9% from respectively patients and clinicians only. With the identification of the FSHD1 and FSHD2 forms, specific questionnaires have been designed. Though FSHD2 patients are progressively included, FSHD1 patients still account for the majority (94.9%). The registry is compatible with the FAIR principles as data are Findable, Accessible and Interoperable. We thus used molecular standards and standardized clinical terms used by the FILNEMUS French network of reference centers for the diagnosis and follow-up of patients suffering from a rare neuromuscular disease. The implemented clinical terms mostly map to dictionaries and terminology systems such as SNOMED-CT (75% of terms), CTV3 (61.7%) and NCIt (53.3%). Because of the sensitive nature of data, they are not directly reusable and can only be accessed as aggregated data after evaluation and approval by the registry oversight committee.

Conclusions

The French National Registry of FSHD patients belongs to a national effort to develop databases, which should now interact with other initiatives to build a European and/or an international FSHD virtual registry for the benefits of patients. It is accessible at www.fshd.fr and various useful information, links, and documents, including a video, are available for patients and professionals.

Keywords

  • Patient registry
  • Database
  • Facioscapulohumeral muscular dystrophy
  • FSHD
  • FSHD1
  • FSHD2
  • Myopathy

No hay comentarios:

Publicar un comentario